Belzutifan Plus Lenvatinib Versus Cabozantinib for Advanced Renal Cell Carcinoma After Anti–PD-(L)1 Therapy: Open-Label Phase 3 LITESPARK-011 Study
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5